Clearance of Inflammatory Cytokines During Renal Replacement Therapy Using the EMIC®2 Filter

NCT03231748 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 12

Last updated 2019-10-23

No results posted yet for this study

Summary

This study will be conducted in patients with sepsis and acute kidney injury needing renal replacement therapy.

The aim is to investigate whether continuous renal replacement therapy with the EMIC®2 filter leads to removal of pro-inflammatory middle molecular weight cytokines from the blood.

Conditions

  • Acute Renal Failure

Sponsors & Collaborators

  • Guy's and St Thomas' NHS Foundation Trust

    lead OTHER

Principal Investigators

  • Marlies Ostermann, PhD · Guy's & St Thomas Hospital London

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-01
Primary Completion
2018-07-01
Completion
2018-07-01

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03231748 on ClinicalTrials.gov